Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Aug 27;25(1):1384.
doi: 10.1186/s12885-025-14228-3.

Bulgarian exploratory analysis of time from diagnosis to treatment of lung cancer patients (Beat) - a retrospective database study on the patient pathway and time from diagnosis to treatment

Assen Dudov  1 , Nikolay Conev  2 , Mila Petrova  3 , Ivan Tonev  4 , Martina Nacheva  5 , Maria V Dimitrova  6 , Maria J Dimitrova  7
Affiliations
Observational Study

Bulgarian exploratory analysis of time from diagnosis to treatment of lung cancer patients (Beat) - a retrospective database study on the patient pathway and time from diagnosis to treatment

Assen Dudov et al. BMC Cancer. .

Abstract

Background: Globocan data for 2020 rank lung cancer as the third most common malignancy (12.1%) and the deadliest cancer (18.3%) in Bulgaria. The current study aims to analyze lung cancer patient pathways and time to treatment from diagnosis based on real-world data.

Methods: We conducted an observational database study based on the secondary use of data collected for other purposes for 3 years (2020-2022). The main outcomes of interest were time from diagnosis to therapy measured in days on national and regional levels, stratified by therapy type and year and number of newly diagnosed patients with lung cancer in each of the years for the observed period. Data were analyzed through descriptive statistics.

Results: Throughout the observed period, 8,585 patients were newly diagnosed with lung cancer, averaging approximately 2,861 diagnoses per year. Most patients' records reported non-small cell lung cancer (4536, 64%), Furthermore, most patients were diagnosed with advanced stages of cancer, with 61% (4297) being diagnosed with Stage IV. Time from Diagnosis to First Treatment (median) outcome showed variance by regions and type, from 7 to 40 days in the case of surgical treatment and 26 to 85 days in the case of combination therapy. The time from Diagnosis to First Systemic Treatment indicator shows a median delay between diagnosis to treatment of 42 days.

Conclusions: The study confirms that dynamic patient registers are crucial for performing real-world studies of treatment patterns and identifying gaps and inequities on a national level. There is a significant need to address the lack of screening programs for lung cancer in Bulgaria and ensure more equitable distribution of oncology centers.

Keywords: Diagnosis; Lung cancer; Patient pathway; Real-world data; Time to treatment.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. The data collection and analysis scope excluded safety and patient involvement reconciliation; therefore, informed ethical permission was not required for the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Regional stratification of patient data collection
See this image and copyright information in PMC

References

    1. Global cancer observatory. Cancer today. Globocan: 2022: Bulgaria. Available at: https://gco.iarc.who.int/media/globocan/factsheets/populations/100-bulga.... Accessed on: March 2024.
    1. Park HJ, Lee SH, Chang YS. Recent advances in diagnostic technologies in lung cancer. Korean J Intern Med. 2020;35(2):257–68. 10.3904/kjim.2020.030. - PMC - PubMed
    1. Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O’Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap world Sci). 2018 Sep-Dec;6(3–4):79–100. 10.1142/S2339547818300020 - PMC - PubMed
    1. Liao J, Li X, Gan Y, Han S, Rong P, Wang W, Li W, Zhou L. Artificial intelligence assists precision medicine in cancer treatment. Front Oncol. 2023;12:998222. 10.3389/fonc.2022.998222. - PMC - PubMed
    1. Maria Dimitrova P, Milushewa E, Petrova D, Mihaylova NT, Guenka Petrova. Triple negative breast cancer in Bulgaria: epidemiological data and treatment patterns based on real world evidence and patient registries. Biotechnol Biotechnol Equip. 2021;35(1):551–9. 10.1080/13102818.2021.1903338.

Publication types

LinkOut - more resources